Back to Global NewsPublished: 7 Mar 2026Download AppJoin TelegramWhy AIM ImmunoTech’s $1.8M Rights Offering May Trigger a Biotech Surge—or Crash#AIM ImmunoTech#Biotech Financing#Rights Offering#Pancreatic Cancer#InvestingDownload AppJoin CommunityShare Article